iRadimed (NASDAQ:IRMD) CEO Sells $503,250.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $100.65, for a total value of $503,250.00. Following the transaction, the chief executive officer owned 2,262,500 shares of the company’s stock, valued at approximately $227,720,625. This represents a 0.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

iRadimed Stock Up 1.3%

NASDAQ:IRMD opened at $99.18 on Friday. The firm’s fifty day simple moving average is $97.18 and its 200 day simple moving average is $80.82. The stock has a market cap of $1.26 billion, a P/E ratio of 60.11 and a beta of 1.09. iRadimed Corporation has a twelve month low of $47.48 and a twelve month high of $104.93.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping the consensus estimate of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The business had revenue of $21.20 million during the quarter, compared to analyst estimates of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, analysts expect that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Dividend Announcement

The company also recently announced a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were issued a dividend of $0.50 per share. The ex-dividend date was Wednesday, December 17th. iRadimed’s dividend payout ratio is 41.21%.

Institutional Trading of iRadimed

Several institutional investors have recently bought and sold shares of IRMD. James Investment Research Inc. bought a new stake in iRadimed during the 4th quarter valued at about $239,000. Cornerstone Investment Partners LLC bought a new stake in shares of iRadimed during the fourth quarter valued at approximately $224,000. Arizona State Retirement System purchased a new position in iRadimed in the 4th quarter worth approximately $225,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in iRadimed by 4.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock worth $567,000 after acquiring an additional 267 shares during the last quarter. Finally, CWM LLC lifted its position in iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after acquiring an additional 107 shares in the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on IRMD shares. Lake Street Capital restated a “buy” rating and set a $100.00 price target on shares of iRadimed in a research report on Monday, November 3rd. Zacks Research raised iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Roth Mkm set a $90.00 target price on shares of iRadimed in a report on Friday, October 31st. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, iRadimed presently has a consensus rating of “Moderate Buy” and an average target price of $95.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.